Toll-Like Receptors Expression and Signaling in Glia Cells in Neuro-Amyloidogenic Diseases: Towards Future Therapeutic Application
暂无分享,去创建一个
[1] H. Aldskogius. Microglia in neuroregeneration , 2001, Microscopy research and technique.
[2] S. Akira,et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5 , 2001, Nature.
[3] S. Akira,et al. A Toll-like receptor recognizes bacterial DNA , 2000, Nature.
[4] H. Neumann,et al. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. , 2005, Brain : a journal of neurology.
[5] Hiroki Toda,et al. Inflammatory Blockade Restores Adult Hippocampal Neurogenesis , 2003, Science.
[6] Holger Heine,et al. Role of the Toll-Like Receptor 4 in Neuroinflammation in Alzheimer’s Disease , 2007, Cellular Physiology and Biochemistry.
[7] C. Brosnan,et al. Astrocyte Indoleamine 2,3-Dioxygenase Is Induced by the TLR3 Ligand Poly(I:C): Mechanism of Induction and Role in Antiviral Response , 2007, Journal of Virology.
[8] R. Ravid,et al. Broad Expression of Toll‐Like Receptors in the Human Central Nervous System , 2002, Journal of neuropathology and experimental neurology.
[9] S. Fahn,et al. Parkinson's disease: Neurodegenerative mechanisms and neuroprotective interventions—report of a workshop , 1998, Movement disorders : official journal of the Movement Disorder Society.
[10] M. Beal,et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury , 1996, Nature Genetics.
[11] Pamela L. Follett,et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[12] U. Müller,et al. Differential regulation of toll-like receptor mRNAs in amyloid plaque-associated brain tissue of aged APP23 transgenic mice , 2009, Neuroscience Letters.
[13] S. Miller,et al. Differential activation of astrocytes by innate and adaptive immune stimuli , 2005, Glia.
[14] F. Crews,et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration , 2007, Glia.
[15] D. Davies,et al. Structural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA , 2008, Science.
[16] S. Akira,et al. Macrophages and Myeloid Dendritic Cells, but Not Plasmacytoid Dendritic Cells, Produce IL-10 in Response to MyD88- and TRIF-Dependent TLR Signals, and TLR-Independent Signals1 , 2006, The Journal of Immunology.
[17] C. Plata-salamán,et al. Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.
[18] Gerd Kempermann,et al. Adult neurogenesis and repair of the adult CNS with neural progenitors, precursors, and stem cells , 2005, Progress in Neurobiology.
[19] Shijie Jin,et al. Tumor Necrosis Factor-α Induces Neurotoxicity via Glutamate Release from Hemichannels of Activated Microglia in an Autocrine Manner* , 2006, Journal of Biological Chemistry.
[20] I. Bechmann,et al. IDO (indolamine 2,3-dioxygenase) expression and function in the CNS. , 2003, Advances in experimental medicine and biology.
[21] W. Schulz-Schaeffer,et al. Screening of innate immune receptors in neurodegenerative diseases: A similar pattern , 2009, Neurobiology of Aging.
[22] F. Mégret,et al. Monique Lafon Producers of Beta Interferon Human Neurons to Become Strong Virus Infection Switches Tlr-3-positive , 2005 .
[23] C. Iadecola,et al. MyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival , 2007, The Journal of experimental medicine.
[24] M. Mattson,et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits , 2007, Proceedings of the National Academy of Sciences.
[25] M. Block,et al. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms , 2007, Nature Reviews Neuroscience.
[26] Guy C. Brown,et al. Inflammatory Neurodegeneration Mediated by Nitric Oxide from Activated Glia-Inhibiting Neuronal Respiration, Causing Glutamate Release and Excitotoxicity , 2001, The Journal of Neuroscience.
[27] S. Yang,et al. Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. , 2000, The Journal of pharmacology and experimental therapeutics.
[28] S. Mckercher,et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis , 2006, Proceedings of the National Academy of Sciences.
[29] S. Akira,et al. The role of Toll-like receptors in immune disorders , 2006, Expert opinion on biological therapy.
[30] C. Lomen‐Hoerth,et al. Amyotrophic Lateral Sclerosis from Bench to Bedside , 2008, Seminars in neurology.
[31] M. Netea,et al. Functional Consequences of Toll-like Receptor 4 Polymorphisms , 2008, Molecular medicine.
[32] Yaniv Ziv,et al. Toll-like receptors modulate adult hippocampal neurogenesis , 2007, Nature Cell Biology.
[33] L. Lue,et al. Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease , 2001, Neurochemistry International.
[34] S. Rivest,et al. Toll‐like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram‐negative bacterial cell wall components , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[35] Richard Mayeux,et al. Epidemiology of neurodegeneration. , 2003, Annual review of neuroscience.
[36] R. Sidman,et al. Toll-Like Receptor 3 Is a Potent Negative Regulator of Axonal Growth in Mammals , 2007, The Journal of Neuroscience.
[37] W. Gong,et al. CpG‐containing oligodeoxynucleotide promotes microglial cell uptake of amyloid β 1–42 peptide by up‐regulating the expression of the G‐protein‐coupled receptor mFPR2 , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[38] A. Aguzzi,et al. The prion's elusive reason for being. , 2008, Annual review of neuroscience.
[39] K. L. Richard,et al. Toll-Like Receptor 2 Acts as a Natural Innate Immune Receptor to Clear Amyloid β1–42 and Delay the Cognitive Decline in a Mouse Model of Alzheimer's Disease , 2008, The Journal of Neuroscience.
[40] B. Liu,et al. The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery , 2008, Fundamental & clinical pharmacology.
[41] J. Deisenhofer,et al. A structural basis of the interactions between leucine-rich repeats and protein ligands , 1995, Nature.
[42] B. Thomas. Parkinson's disease: from molecular pathways in disease to therapeutic approaches. , 2009, Antioxidants & redox signaling.
[43] K. Ishii,et al. The LPS receptor (CD14) links innate immunity with Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[44] S. Paik,et al. Crystal Structure of the TLR1-TLR2 Heterodimer Induced by Binding of a Tri-Acylated Lipopeptide , 2007, Cell.
[45] H. Hagberg,et al. The role of Toll-like receptors in perinatal brain injury. , 2009, Clinics in perinatology.
[46] G. Bing,et al. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration , 2003, Neurobiology of Disease.
[47] Soo Young Park,et al. Gangliosides trigger inflammatory responses via TLR4 in brain glia. , 2006, The American journal of pathology.
[48] Adriano Aguzzi,et al. Pathogenesis of prion diseases: current status and future outlook , 2006, Nature Reviews Microbiology.
[49] R. Sidman,et al. TLR8: An Innate Immune Receptor in Brain, Neurons and Axons , 2007, Cell cycle.
[50] L. Tong,et al. Structural basis for signal transduction by the Toll/interleukin-1 receptor domains , 2000, Nature.
[51] M. Gurney,et al. Mutant CuZn superoxide dismutase in motor neuron disease , 1998, Journal of Inherited Metabolic Disease.
[52] S. Miller,et al. Innate and adaptive immune responses of the central nervous system. , 2006, Critical reviews in immunology.
[53] J. Julien,et al. Exacerbation of Motor Neuron Disease by Chronic Stimulation of Innate Immunity in a Mouse Model of Amyotrophic Lateral Sclerosis , 2004, The Journal of Neuroscience.
[54] R. Nitsch,et al. A Vicious Cycle Involving Release of Heat Shock Protein 60 from Injured Cells and Activation of Toll-Like Receptor 4 Mediates Neurodegeneration in the CNS , 2008, The Journal of Neuroscience.
[55] E. Dagand,et al. TLR2 Mediates Neuroinflammation and Neuronal Damage1 , 2007, The Journal of Immunology.
[56] G. Nicolardi,et al. Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson's-like disease. , 2008, Immunopharmacology and immunotoxicology.
[57] R. Paczynski,et al. Treating brain swelling , 1996, Neurology.
[58] M. Arditi,et al. Cooperation of Toll-Like Receptor 2 and 6 for Cellular Activation by Soluble Tuberculosis Factor and Borrelia burgdorferi Outer Surface Protein A Lipoprotein: Role of Toll-Interacting Protein and IL-1 Receptor Signaling Molecules in Toll-Like Receptor 2 Signaling1 , 2001, The Journal of Immunology.
[59] J. Cano,et al. Lipopolysaccharide Intranigral Injection Induces Inflammatory Reaction and Damage in Nigrostriatal Dopaminergic System , 1998, Journal of neurochemistry.
[60] K. Abel,et al. Immune defects in Alzheimer's disease: new medications development , 2008, BMC Neuroscience.
[61] A. Davies,et al. Bacterial lipopolysaccharide regulates nociceptin expression in sensory neurons , 2008, Journal of neuroscience research.
[62] Ling Li,et al. Role of toll-like receptor signalling in Abeta uptake and clearance. , 2006, Brain : a journal of neurology.
[63] M. Mattson,et al. Toll-Like Receptor 3 Is a Negative Regulator of Embryonic Neural Progenitor Cell Proliferation , 2008, The Journal of Neuroscience.
[64] I. Bertini,et al. Metal-free superoxide dismutase forms soluble oligomers under physiological conditions: A possible general mechanism for familial ALS , 2007, Proceedings of the National Academy of Sciences.
[65] J. Tavernier,et al. TLR-4, IL-1R and TNF-R signaling to NF-κB: variations on a common theme , 2008, Cellular and Molecular Life Sciences.
[66] J. Wiltfang,et al. Amyloid beta peptide 1–40 enhances the action of Toll‐like receptor‐2 and ‐4 agonists but antagonizes Toll‐like receptor‐9‐induced inflammation in primary mouse microglial cell cultures , 2005, Journal of neurochemistry.
[67] Douglas R. McDonald,et al. A Cell Surface Receptor Complex for Fibrillar β-Amyloid Mediates Microglial Activation , 2003, The Journal of Neuroscience.
[68] T. Kielian,et al. The role of Toll‐like receptors in CNS response to microbial challenge , 2006, Journal of neurochemistry.
[69] R. Sidman,et al. Toll-like receptor 8 functions as a negative regulator of neurite outgrowth and inducer of neuronal apoptosis , 2006, The Journal of cell biology.
[70] D. Feinstein,et al. The Clinical Course of Experimental Autoimmune Encephalomyelitis is Associated with a Profound and Sustained Transcriptional Activation of the Genes Encoding Toll‐like Receptor 2 and CD14 in the Mouse CNS , 2002, Brain pathology.
[71] S. Akira,et al. Prion pathogenesis in the absence of Toll‐like receptor signalling , 2003, EMBO reports.
[72] F. Mégret,et al. The innate immune facet of brain , 2007, Journal of Molecular Neuroscience.
[73] D. Wilcock,et al. Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice , 2001, Neurobiology of Aging.
[74] L. Adorini,et al. Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. , 1998, Journal of immunology.
[75] W. Brück,et al. Differential regulation of myelin phagocytosis by macrophages/microglia, involvement of target myelin, Fc receptors and activation by intravenous immunoglobulins , 2002, Journal of neuroscience research.
[76] K. Fassbender,et al. Innate immune receptor expression in normal brain aging , 2007, Neuroscience.
[77] 土井 由紀子. Microglia activated with Toll-like receptor 9 ligand CpG attenuate oligomeric amyloid β neurotoxicity in vitro and in vivo models of Alzheimer's disease , 2009 .
[78] J. Julien,et al. Extracellular mutant SOD1 induces microglial‐mediated motoneuron injury , 2010, Glia.
[79] Hayyoung Lee,et al. The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex , 2009, Nature.
[80] N. Gay,et al. Drosophila Toll and IL-1 receptor , 1991, Nature.
[81] C. Gazzaruso,et al. Effect of the functional toll-like receptor 4 Asp299Gly polymorphism on susceptibility to late-onset Alzheimer's disease , 2006, Neuroscience Letters.
[82] J. Antel,et al. TLR Signaling Tailors Innate Immune Responses in Human Microglia and Astrocytes1 , 2005, The Journal of Immunology.
[83] D. Cleveland,et al. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease , 2007, Nature Neuroscience.
[84] R. Coffman,et al. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists , 2007, Nature Medicine.
[85] T. Morgan,et al. Peroxynitrite Mediates Neurotoxicity of Amyloid β-Peptide1–42- and Lipopolysaccharide-Activated Microglia , 2002, The Journal of Neuroscience.
[86] S. McBride. Prion protein: a pattern recognition receptor for viral components and uric acid responsible for the induction of innate and adaptive immunity. , 2005, Medical hypotheses.
[87] H. S. Warren,et al. Toll-like receptors. , 2005, Critical care medicine.
[88] G. Landreth,et al. CD14 and Toll-Like Receptors 2 and 4 Are Required for Fibrillar Aβ-Stimulated Microglial Activation , 2009, The Journal of Neuroscience.
[89] Jie-Oh Lee,et al. Structures of the toll-like receptor family and its ligand complexes. , 2008, Immunity.
[90] A. Aderem,et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[91] G. Hardiman,et al. A family of human receptors structurally related to Drosophila Toll. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[92] Patrick Couvreur,et al. Role of spleen macrophages in the clearance of scrapie agent early in pathogenesis , 2000, The Journal of pathology.
[93] H. Braak,et al. Staging of Alzheimer-related cortical destruction. , 1997, International psychogeriatrics.
[94] J. Edwardson,et al. Chronic glial activation, neurodegeneration, and APP immunoreactive deposits following acute administration of double‐stranded RNA , 2003, Glia.
[95] P. Scumpia,et al. Double‐stranded RNA signals antiviral and inflammatory programs and dysfunctional glutamate transport in TLR3‐expressing astrocytes , 2005, Glia.
[96] C. Janeway,et al. The immune system evolved to discriminate infectious nonself from noninfectious self. , 1992, Immunology today.
[97] I. Bechmann,et al. A Mechanism for Neurodegeneration Induced by Group B Streptococci through Activation of the TLR2/MyD88 Pathway in Microglia1 , 2006, The Journal of Immunology.
[98] Adriano Aguzzi,et al. Molecular mechanisms of prion pathogenesis. , 2008, Annual review of pathology.
[99] R. Crowther,et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .
[100] S. Akira,et al. A Critical Role of Toll-like Receptor 2 in Nerve Injury-induced Spinal Cord Glial Cell Activation and Pain Hypersensitivity* , 2007, Journal of Biological Chemistry.
[101] T. Wisniewski,et al. Accelerated Prion Disease Pathogenesis in Toll-Like Receptor 4 Signaling-Mutant Mice , 2008, Journal of Virology.
[102] R. Ravid,et al. Toll‐like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators , 2006, Glia.
[103] A. Bowie,et al. The human adaptor SARM negatively regulates adaptor protein TRIF–dependent Toll-like receptor signaling , 2006, Nature Immunology.
[104] C. Caruso,et al. TLR4 Polymorphisms and Ageing: Implications for the Pathophysiology of Age-Related Diseases , 2009, Journal of Clinical Immunology.
[105] S. Rivest,et al. Circulating cell wall components derived from gram‐negative, not gram‐positive, bacteria cause a profound induction of the gene‐encoding Toll‐like receptor 2 in the CNS , 2001, Journal of neurochemistry.
[106] D. Farfara,et al. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease , 2008, Journal of cellular and molecular medicine.
[107] H. Soininen,et al. Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in alzheimer's disease , 1995, Neuroscience.
[108] J. Fazakerley,et al. In response to pathogens, glial cells dynamically and differentially regulate Toll-like receptor gene expression , 2005, Journal of Neuroimmunology.
[109] H. Weiner,et al. A nasal proteosome adjuvant activates microglia and prevents amyloid deposition , 2008, Annals of neurology.
[110] Makoto Hashimoto,et al. Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.
[111] J. Rossiter,et al. Expression of Toll-like receptor 3 in the human cerebellar cortex in rabies, herpes simplex encephalitis, and other neurological diseases , 2006, Journal of NeuroVirology.
[112] S. Miller,et al. Microglia Initiate Central Nervous System Innate and Adaptive Immune Responses through Multiple TLRs1 , 2004, The Journal of Immunology.
[113] U. Heinemann,et al. Interleukin 4 and interleukin 10 levels are elevated in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. , 2005, Archives of neurology.
[114] N. Johnson,et al. Viruses selectively upregulate Toll-like receptors in the central nervous system. , 2005, Biochemical and biophysical research communications.
[115] Pamela L. Follett,et al. The Toll-Like Receptor TLR4 Is Necessary for Lipopolysaccharide-Induced Oligodendrocyte Injury in the CNS , 2002, The Journal of Neuroscience.
[116] C. Janeway,et al. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity , 1997, Nature.
[117] P. Dobrzanski,et al. Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease , 1998, Brain Research.
[118] J. Ringman,et al. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin , 2007, Proceedings of the National Academy of Sciences.
[119] D. Davies,et al. The TLR3 signaling complex forms by cooperative receptor dimerization , 2008, Proceedings of the National Academy of Sciences.
[120] A. Aderem,et al. Cutting Edge: Functional Interactions Between Toll-Like Receptor (TLR) 2 and TLR1 or TLR6 in Response to Phenol-Soluble Modulin1 , 2001, The Journal of Immunology.
[121] A. Bailey,et al. Who Is at Risk and Why? Teachers' Reasons for Concern and Their Understanding and Assessment of Early Literacy , 2006 .
[122] S. Lockett,et al. Activation of Toll-like Receptor 2 on Microglia Promotes Cell Uptake of Alzheimer Disease-associated Amyloid β Peptide* , 2006, Journal of Biological Chemistry.
[123] R. Ravid,et al. Identification of soluble CD14 as an endogenous agonist for Toll‐like receptor 2 on human astrocytes by genome‐scale functional screening of glial cell derived proteins , 2007, Glia.
[124] Sumana Chakravarty,et al. Toll-Like Receptor 4 on Nonhematopoietic Cells Sustains CNS Inflammation during Endotoxemia, Independent of Systemic Cytokines , 2005, The Journal of Neuroscience.
[125] H. Kretzschmar,et al. Postexposure prophylaxis against prion disease with a stimulator of innate immunity , 2002, The Lancet.